NASDAQ:CMMB
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. reported net income of −$27.6M in fiscal 2022. Free cash flow was −$20.4M, and the diluted share count rose 9.7%.Summary generated from Chemomab Therapeutics Ltd.'s SEC filings. Latest annual report filed Mar 20, 2023.
Key statistics
Fiscal 2022 from SEC filings. MethodologyRevenue (FY22)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−56.6%
Debt / equityn/a
Free cash flow−$20.4M
FCF marginn/a
Share count change+9.7%
Financials
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | n/a | n/a |
| Net income | −14 | −27 | −6 | −12 | −28 |
| Free cash flow | −14 | −17 | −5 | −13 | −20 |
Recent filings
- 4Insider transaction report
Sep 1, 2026 - 4Insider transaction report
Jun 1, 2026 - 8-KDirector or officer change
Jun 16, 2023 - 8-KDirector or officer change
Jun 5, 2023 - 8-KResults of operations and financial condition
May 11, 2023 - 10-QQuarterly report for the period ended Mar 31, 2023
May 11, 2023 - 10-KAnnual report for the fiscal year ended Dec 31, 2022
Mar 20, 2023 - 8-KOther events
Feb 21, 2023